The effects of RPL554 on top of standard COPD reliever medications
Research type
Research Study
Full title
A phase II, randomised, double blind, placebo controlled, six way crossover study to assess the bronchodilator effect of RPL554 administered on top of salbutamol and ipratropium in patients with COPD
IRAS ID
184901
Contact name
Katharine Abbott-Banner
Contact email
Sponsor organisation
Verona Pharma plc
Eudract number
2015-002536-41
Duration of Study in the UK
0 years, 4 months, 15 days
Research summary
The purpose of this study is to assess the bronchodilator effect (opening of the airways) of RPL554 when used in combination with standard bronchodilator treatment in moderate chronic obstructive pulmonary disease (COPD) patients.
This study is a Phase IIa, randomised, double blind, placebo controlled, six way crossover study to investigate combination treatment with nebulised RPL554 and salbutamol or ipratropium compared to salbutamol or ipratropium alone.
The aim is for each of the 30 patients enrolled to complete six separate 1 day treatment visits. At each of these visits the patient will receive a single dose from a blinded inhaler containing salbutamol or matching placebo (Dummy drug containing no active ingredient), followed by a single dose from a second blinded inhaler containing ipratropium or matching placebo. This will then be followed by a single blinded dose of the RPL554 or placebo.
REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
15/EM/0307
Date of REC Opinion
29 Jul 2015
REC opinion
Further Information Favourable Opinion